Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 44.02B | 41.72B | 32.38B | 27.81B | 21.81B | 16.77B |
Gross Profit | 24.65B | 23.85B | 19.25B | 15.86B | 12.59B | 9.62B |
EBITDA | 12.06B | 11.53B | 9.23B | 7.98B | 6.51B | 4.88B |
Net Income | 7.51B | 7.28B | 4.61B | 4.27B | 3.25B | 2.48B |
Balance Sheet | ||||||
Total Assets | 149.48B | 143.02B | 122.45B | 98.57B | 62.06B | 57.85B |
Cash, Cash Equivalents and Short-Term Investments | 35.63B | 32.18B | 14.47B | 22.78B | 13.19B | 19.90B |
Total Debt | 53.83B | 46.89B | 37.83B | 20.40B | 17.80B | 19.45B |
Total Liabilities | 70.98B | 64.54B | 51.77B | 34.04B | 30.89B | 29.60B |
Stockholders Equity | 78.05B | 78.02B | 70.59B | 64.54B | 31.18B | 28.25B |
Cash Flow | ||||||
Free Cash Flow | 10.41B | 12.57B | -2.27B | 2.12B | 2.49B | 952.00M |
Operating Cash Flow | 12.15B | 14.69B | -17.00M | 4.06B | 3.81B | 3.18B |
Investing Cash Flow | -7.01B | -3.47B | -24.86B | -22.77B | -8.10B | -9.08B |
Financing Cash Flow | 12.62B | 6.48B | 16.58B | 28.30B | -2.41B | 18.11B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
66 Neutral | ¥276.67B | 44.46 | 0.37% | 29.09% | 87.01% | ||
51 Neutral | $7.91B | -0.36 | -41.71% | 2.23% | 23.45% | -1.86% | |
― | €298.04M | 15.79 | 15.71% | ― | ― | ― | |
― | €459.53M | 52.34 | 8.00% | ― | ― | ― | |
79 Outperform | ¥21.51B | 18.77 | 1.91% | -6.29% | -22.25% | ||
73 Outperform | ¥141.15B | 19.27 | 1.80% | 10.66% | 0.41% | ||
43 Neutral | ¥21.72B | 4,465.71 | 1.13% | -0.58% | -260.22% |
JMDC Inc. reported significant financial growth for the first quarter ending June 30, 2025, with a 32.5% increase in revenue and a 48.8% rise in operating profit compared to the same period last year. This growth reflects the company’s strategic focus on its core operations after discontinuing its dispensing pharmacy support business, enhancing its market positioning and potentially increasing shareholder value.
JMDC Inc. has finalized the details of share subscription rights to be issued to its directors, executive officers, and employees, as well as those of its subsidiaries. This move, decided in a board meeting on June 25, 2025, involves the issuance of 6,840 share subscription rights, allowing for the exercise of 684,000 common shares, potentially impacting the company’s equity structure and aligning employee interests with corporate growth.
JMDC Inc. has announced that OMRON Corporation has become its new parent company after acquiring a majority stake through a tender offer. Despite this change, JMDC maintains operational independence with no business dependence on OMRON, ensuring protection for minority shareholders in any potential transactions.
JMDC Inc. announced the issuance of share subscription rights to its directors, executive officers, and employees, as well as those of its subsidiaries, to enhance motivation and attract talent. This move is part of JMDC’s strategy to expand its business and achieve medium-term goals, ultimately enhancing corporate and shareholder value while maintaining reasonable share dilution.